Zhejiang Medicine (600216.SS) Earnings Analysis
Zhejiang Medicine (600216.SS) next reports earnings on 2026-08-26, consensus EPS 0.25 CNY. Last quarter (2026-04-24) it missed with EPS 0.3 CNY vs 0.39 CNY est (-23.1%). It has beaten estimates in 0/2 recent quarters (0%). Trailing P/E 15.52.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 600216.SS next report earnings?
| Next earnings date | 2026-08-26 |
|---|---|
| Consensus EPS estimate | 0.25 CNY |
| Revenue estimate | 2.19B |
600216.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-24 | 0.3 CNY | 0.39 CNY | -23.1% | Miss |
| 2026-04-11 | -0.05 CNY | -0.04 CNY | -25% | Miss |
| 2025-03-31 | 0.43 CNY | n/a | n/a | n/a |
| 2024-10-24 | 0.556 CNY | n/a | n/a | n/a |
| 2024-08-22 | 0.2139 CNY | n/a | n/a | n/a |
Beat rate: 0/2 (0%) over reported quarters with consensus data.
600216.SS valuation and analyst view
| Trailing P/E | 15.52 |
|---|---|
| Trailing EPS | 0.7853 CNY |
| Price / book | 1.04 |
| Dividend yield | 2.29% |
| Market cap | 11.74B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Zhejiang Medicine (600216.SS)'s next earnings date?
Zhejiang Medicine is next scheduled to report on 2026-08-26, with a consensus EPS estimate of 0.25 CNY and revenue estimate of 2.19B.
Did 600216.SS beat earnings last quarter?
In its 2026-04-24 report, 600216.SS posted EPS of 0.3 CNY versus a 0.39 CNY estimate — a miss of 23.1%.
What is 600216.SS's earnings track record?
Over the last 2 reported quarters with consensus data, 600216.SS beat estimates 0 times (0%).
What is 600216.SS's current P/E ratio and EPS?
600216.SS trades at a trailing P/E of 15.52 on trailing EPS of 0.7853047414428886 CNY.
What do analysts rate 600216.SS?
600216.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.